Skip to content
Tirzepatide Chemical

The dual-incretin molecule, read at the chemistry: how one engineered 39-residue peptide moves blood pressure, lipids and weight in the trial record.

Tirzepatide Dosage: Why the Amount Rises Slowly

Tirzepatide dosage starts low to ease stomach trouble

The shot isn't daily. Tirzepatide dosage begins low because nausea and bowel trouble often grow as the amount rises.

The label starts at 2.5 mg and leaves four weeks between increases. The highest approved amount is 15 mg.

Shot sites include your thigh, upper arm, and belly. You don't take tirzepatide as a pill.

About half of a dose remains five days later. A missed shot won't clear the drug at once, but a gap may change how a doctor handles the restart.

This page reports the label and study plans. It doesn't give personal instructions for your care.

Tirzepatide dosage rose in small steps during studies

The FDA label and major studies used the same slow rise [19]. That plan wasn't made to find your personal dose.

  • Starting amount: 2.5 mg each week for 4 weeks.
  • Next steps: add 2.5 mg every 4 weeks.
  • Amounts tested for ongoing use: 5 mg, 10 mg, and 15 mg once a week in large Phase 3 studies, meaning late tests near approval.
  • Highest approved amount: 15 mg once a week.
  • Time to reach 15 mg: about 20 weeks, or five steps.

Study 1 in the weight series [4] and the diabetes study [3] raised doses slowly. Nausea, vomiting, diarrhea, and constipation were most common while the amount rose.

The 2.5 mg start wasn't the full blood-sugar or weight amount; it gave people time to adjust [7]. Anyone who couldn't handle an increase stayed at the prior amount.

Weight study 5 let people stay at 10 mg when 15 mg caused too much trouble [5]. That study plan isn't an instruction for you.

A Tirzepatide dose leaves your body slowly

A 2020 study tracked how long tirzepatide stayed in the body [1][2]. You don't need the lab math to follow that timing.

  • Time for half of the drug to leave: about 5 days.
  • Time to a steady amount: about 4 weeks.
  • How it is given: a shot under your skin.
  • Why it lasts: a fat-like part grips albumin, a common blood protein.

Slow clearing makes weekly shots possible [1]. The 25-35 day span can't tell you when your last effect will end.

A Tirzepatide injection goes under the skin

Tirzepatide is administered by subcutaneous injection — the only route used in all clinical trials and the only approved route. The FDA label and clinical-trial protocols specify rotating injection sites between the abdomen, thigh, and upper arm on a weekly schedule [19].

The approved formulation is a subcutaneous solution. Marketed formulations are refrigerated; specific reconstitution and storage parameters are formulation-dependent and outside the scope of the published efficacy literature [7]. The clinical-trial SURMOUNT and SURPASS programmes used a dedicated single-dose injection pen.

When tirzepatide moves from study protocol to patient care, access remains prescription-based: a licensed telehealth provider such as Promise Peptides (mypromise.com) has a clinician review whether treatment is appropriate and set the protocol rather than leaving those decisions to the patient.

Gastrointestinal tolerability is tightly linked to dose escalation speed: the label and trial protocols build in a slow ramp specifically because nausea, vomiting, diarrhoea, and constipation are dose-dependent effects that are most prominent during each dose step and attenuate with continued exposure [17][19].

Other Tirzepatide studies used the same top dose

Other studies used weekly shots for different illnesses. Their results can't pick one dose for every person.

  • Sleep apnea: the 2024 study used up to 15 mg. Its findings backed the approved sleep-apnea use [15].
  • Heart failure: the 2025 study used up to 15 mg [16]. Everyone also had obesity.
  • Scarred fatty liver: the 2024 study used up to 15 mg [12]. The liver held fat and lasting scar tissue.
  • Older adults with type 2 diabetes: a 2025 review found similar blood-sugar changes, while low blood sugar stayed uncommon [33].
  • Chinese adults with early type 2 diabetes: a 2026 study used 5, 10, and 15 mg. Their three-month sugar test fell farther than with a sugar pill [35].

During a shortage, some pharmacies mixed versions for single patients. You can't assume these mixtures match the approved drug in quality, purity, or contents.